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Original Article
Objectives: This study aims to investigate trends of cardiovascular disease (CVD) risk factor profiles over 17 years in percutaneous cor-
onary intervention (PCI) patients at the Mayo Clinic.
Methods: We performed a time-trend analysis within the Mayo Clinic PCI Registry from 1994 to 2010. Results were the incidence and 
prevalence of CVD risk factors as estimate by the Framingham risk score.
Results: Between 1994 and 2010, 25 519 patients underwent a PCI. During the time assessed, the mean age at PCI became older, but 
the gender distribution did not change. A significant trend towards higher body mass index and more prevalent hypercholesterol-
emia, hypertension, and diabetes was found over time. The prevalence of current smokers remained unchanged. The prevalence of 
ever-smokers decreased among males, but increased among females. However, overall CVD risk according to the Framingham risk 
score (FRS) and 10-year CVD risk significantly decreased. The use of most of medications elevated from 1994 to 2010, except for 
β-blockers and angiotensin converting enzyme inhibitors decreased after 2007 and 2006 in both baseline and discharge, respectively.
Conclusions: Most of the major risk factors improved and the FRS and 10-year CVD risk declined in this population of PCI patients. 
However, obesity, history of hypercholesterolemia, hypertension, diabetes, and medication use increased substantially. Improvements 
to blood pressure and lipid profile management because of medication use may have influenced the positive trends.
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INTRODUCTION
Cardiovascular disease (CVD) is the one of major cause of 
mortality and morbidity in the world. CVD made up to 17.3 
million of global deaths in 2008, among which 7.6 million were 
due to coronary heart disease (CHD). In 2007, one-quarter of 
all deaths in the US originated from heart diseases, nearly 700 
000 deaths in one year. CVD mortality and morbidity are also 
increasing due to sociodemographic, economic, and lifestyle 
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transitions in developing countries [1]. However, CVD mortality 
decreased over 20 years, likely caused by a decrease in smok-
ing and consumption of saturated fat, improved control of car-
diovascular risk factors (cvRF) in general and clinical treatment 
of acute coronary disease in developed countries [1]. However, 
morbidity continued high rate and CVD is nevertheless the one 
of major cause of premature death in developed countries [2]. 
CVD have been related to many risk factors, and about 75% 
of CVD can be caused by traditional risk factors [3]. Although, 
in the overall population, the prevalence of cvRF have de-
clined during the past 30 years [4], there is a vague informa-
tion on the temporal trends of cvRF profiles [5], especially 
among patients referred for a percutaneous coronary inter-
vention (PCI). The recognition of trends in cvRF profiles is im-
portant, especially as the current risk prediction models such 
as the Framingham risk score (FRS) are based on risk profiles 
from decades prior.
Thus, the purpose of this study was to investigate the trend 
in cvRF and the FRS in patients undergoing PCI in the hospital-
based registry over a 17-year period. Temporal trends in the 
medical treatments used as well as the usefulness and predict-
ability of the FRS in patients undergoing PCI were evaluated. 
METHODS
Patients Selection
We analyzed data of all PCI patients included in the Mayo 
Clinic PCI Registry in Rochester, Minnesota from January 1, 1994 
to December 31, 2010 were included in this study. Patients un-
dergoing PCI were prospectively followed in the registry that 
collected demographic, clinical, angiographic, and procedural 
data. Immediate and in-hospital events were recorded, and 
each patient was surveyed by telephone using a standardized 
questionnaire at 6 months and 1 year after the procedure, and 
then annually. The supervisor of this registry audited 10% of all 
records for data integrity. Relevant clinical information was ab-
stracted from medical records. For patients who underwent 
multiple PCIs within a single hospitalization, only the first PCI of 
that hospitalization was included. This study was approved by 
the Mayo Clinic Institutional review board, and patients who 
denied use of their records for research were excluded (n=530, 
653 hospitalizations). During the study period, 26 172 PCI hos-
pitalizations of 20 711 unique patients were performed. After 
exclusion for patients who refused authorization of their re-
cords, 25 519 hospitalizations were included for analysis.
Collected Information
Data retrieved from the PCI Registry included general char-
acteristics (hospital ID, date of the PCI, age, sex, and family his-
tory of heart disease) and cvRF profiles (smoking status, pres-
ence of diabetes mellitus [DM], hypertension, hypercholester-
olemia, height, and weight) [6]. Medicine use at baseline (with-
in 3 days before the PCI) and at discharge was recorded if pa-
tients were taking aspirin, β-blocker, angiotensin converting 
enzyme (ACE) inhibitor, or any other lipid lowering drugs. Hy-
percholesterolemia was defined as a history of higher than 240 
mg/dL for total cholesterol. Hypertension was defined as a 
documented history of hypertension that was being treated 
with medication. A patient was considered to have a history of 
myocardial infarction (MI) if MI occurred at least 7 days prior to 
PCI. Cholesterol and blood pressure (BP) values were retrieved 
from electronic medical records. BP values within one year pri-
or to PCI were deemed acceptable; if multiple measures were 
found, the measure occurring on the date closest to PCI was re-
corded. BP values within one year prior to PCI were acceptable; 
if multiple measures were found, the measure occurring on the 
date closest to PCI was recorded. Cholesterol values within 2 
years and prior to 2 months post PCI were acceptable; the 
maximum value (minimum for high-density lipoprotein cho-
lesterol [HDL-C]) recorded closest to the PCI was recorded in 
the event of multiple measurements. These data were used to 
calculate the estimated risk of CVD using the FRS sheet [7], and 
cvRFs were treated as absent if data required for calculating 
the FRS were missing.
Statistics
Continuous variables are presented as mean±standard de-
viation or as median (interquartile range, Q1, Q3). Discrete data 
are presented as frequencies and percentages. Patients were 
stratified into three groups of 5-year intervals based on the 
date of the PCI to analyze trends among variables. The three 
groups included patients who had a PCI in 1994 to 1999, 2000 
to 2005, or 2006 to 2010, respectively. Analysis of variance with 
a linear contrast analysis was used to assess the trend among 
continuous variables, and the Cochran-Armitage trend test was 
used for comparison of proportions in the total population as 
well as within gender subgroups. Additionally, using linear re-
gression for continuous variables and logistic regression for bi-
nary variables, we tested whether an interaction existed be-
tween gender and time to understand if the linear trend over 
time for men and women was identical.
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Figure 1. Distribution of total percutaneous coronary intervention (PCI) patient population (A) and age (B) by the year and by 
gender from 1994 to 2010.
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All statistical analyses were performed with SAS version 9.2 
(SAS Inc., Cary, NC, USA). All tests were 2-tailed with a signifi-
cance level of 0.05.
RESULTS
A total of 25 519 underwent a PCI at the Mayo Clinic and 
gave permission for follow-up from 1994 to 2010. The clinical 
characteristics and the FRS 5-year trends of the 25 519 patients 
in the 3 periods are presented in Supplemental Table 1. The 
number of patients who underwent a PCI initially increased 
from 1994 to 1999, then plateaued from 2000 to 2005, and fi-
nally decreased from 2006 to 2010 (p for trend<0.001). For the 
total population, the mean age was 66.5±12.1 years, and 18 
068 (71%) patients were male. The mean age when patients 
received a PCI slightly increased across each interval (p for 
trend<0.001), but males still comprised the majority of pa-
tients throughout follow up (p for trend =0.520).
BP and lipid profiles improved for the patients who received 
a PCI most recently (p for trend<0.001); however, body mass 
index (BMI), hypercholesterolemia, hypertension, and DM 
showed an increasing trend (p for trend<0.001). Ten-year CVD 
risk and the FRS increased from 1994 to 1999, decreased from 
2000 to 2006, and then slightly increased from 2006 to 2010. In 
men and women, the FRS and 10-year CVD risk tended to de-
crease over time (p for trend<0.001 for all). However, the FRS 
was higher in women than that in men for all intervals. The 10-
year CVD risk was higher in men than that in women for all in-
tervals (p for trend<0.001 men vs. women). The prevalence of 
ever-smokers decreased in men (p for trend<0.001), but in-
creased in women (p=0.042). Systolic BP, diastolic BP, low-den-
sity lipoprotein cholesterol (LDL-C), DM, and hypertension 
showed a significantly different trend between the genders (p 
for trend<0.001 men vs. women). However, age, total choles-
terol, HDL-C, and the proportion of current smokers were not 
significantly different between genders over time (Supplemen-
tal Table 1, Figures 1-3).
Supplemental Table 2 presents the trends of BMI and num-
ber of patients with a history of hypercholesterolemia and/or 
MI over the three intervals. The mean BMI and proportion of 
patients with a history of hypercholesterolemia increased over 
time, however they varied by time, and were different be-
tween genders (p for trend<0.001 men vs. women). The pro-
portion of female patient with a history of MI was higher than 
male over time, but no significant difference of trend between 
each gender-specific trend was found (Figure 4).
Supplemental Table 3 shows trends relating to the use of 
pharmacological treatments over time. The use of most of 
medications increased over time, but β-blockers dramatically 
declined after 2007 and ACE inhibitors after 2006 at both base-
line and discharge. ACE inhibitor use and lipid lowering drug 
use on discharge significantly differed over time between the 
genders (p for trend=0.003 in ACE inhibitor, 0.016 in lipid low-
ering drug, men vs. women) (Figure 5). 
The average number of points that contributed to the total 
FRS for each component was plotted in Figure 3. Age was not 
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added to the plot because the average was around 5.5 to 6 
points and was flat, so it hindered the ability to see the other 
trends. According to our plot, BP and HDL-C had the greatest 
influence on the FRS calculation. 
DISCUSSION
Despite the decline of CHD mortality, CHD remains the one 
of major cause of mortality in America. However, few studies 
have reported on cvRF status of PCI patients, and pervious re-
sults have been controversial. One study reported a progres-
sive rise in the risk profile of patients undergoing PCI [8]. Our 
large single-center registry study adds to the previous studies 
by reporting on the temporal trends and characteristics of 
cvRFs using recent data. 
Identifying changes to underlying risk factors is important 
for future planning on medical policies and administration for 
prevention. cvRFs of CHD co-act to increase CHD risk [9]. There-
fore, integrated predictors or indicators for clinical and epide-
miological evaluation and the prediction of disease status and 
prognosis are needed.
In this study, we revealed a decreasing trend for the FRS and 
10-year CVD risk over time, likely due to the significant de-
crease in BP and increase in HDL-C as a result of medication ef-
fects or therapeutic interventions. We have suggested this rela-
tionship by analyzing the trend of each cvRF and the changes 
to the contribution of each risk factor to the total FRS by year. 
The concept of cvRFs and the FRS has lead to the develop-
ment of effective managements and preventive intervention 
in clinical management and the ability to estimate global risk 
scores of CHD. The FRS [10] is usually used score to estimate an 
10-year risk of CVD. But, in spite of the ready used application 
of the FRS, it can be limited to apply the certain patients [11]. 
Atherosclerosis often does so as a life-threatening condition 
(examples, acute MI or stroke). Some of them previously would 
have been grouped as at low or moderate risk by the FRS [12]. 
Our results also suggest that there are limitations and in apply-
ing the FRS to PCI patients. 
We found that the FRS had a higher trend in women than 
men; however, the 10-year CVD risk remained higher in men 
than did women over time. The data regarding gender varia-
tion, mechanism, and outcome effect with CHD are very com-
plicated and controversial [13]. The mechanism underlying the 
10-year lag in CHD development in women is not completely 
understood, but may be related, at least in part, to the protec-
tive effects of endogenous estrogen in premenopausal wom-
en. Overall, the risk factor prevalence in women was higher 
than that in men. The risk factor prevalence in female should 
be much higher than that in male to lead to the onset of CHD 
at the same age as in male, because CHD typically appears 10 
years later in female [14].
Over time, the mean age that patients underwent PCI be-
came older in our study. Advancing age is a contributing fac-
tor for the development of CHD in men and women [15]. Fe-
male tend to comprise the majority of older adults, and this 
demographic change has important implications for providing 
health care. This trend in increasing age over time may have 
originated because age increases the absolute baseline risk; 
Figure 2. Trend of the Framingham risk score (A) and 10-year cardiovascular disease (CVD) risk (B) by gender in patients having 
percutaneous coronary intervention from 1994 to 2010. 
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Figure 3. Trends of the components of Framingham risk score, including systolic blood pressure (BP) (A), diastolic BP (B), total 
cholesterol (C), low-density lipoprotein cholesterol (LDL-C) (D), high-density lipoprotein cholesterol (HDL-C) (E), hypertension (F), 
diabetes (G), and smoking (H) among percutaneous coronary intervention patients from 1994 to 2010.
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therefore, risk factor free patient will tend to present for a PCI 
at a much older age once their absolute baseline risk increases 
sufficiently to evoke a significant disease prevalence [16]. 
Moreover, this result may have been due to a survivor bias be-
cause patients with traditional risk factors tend to expire at 
more young age than those without traditional risk factors do 
[16].
Systolic BP is the most prominent risk factor as a target for 
treatment and for prognosis [17]. Combined systolic and dia-
stolic hypertension and isolated systolic hypertension are doc-
umented risks for morbidity and onset of CHD in both genders 
[18]. In this study, BP declined rapidly, however the presence of 
hypertension increased continuously over time because hyper-
tension was defined as a documented history of hypertension 
being treated with medication. Our result also showed that the 
trend for systolic BP, diastolic BP, and hypertension were signifi-
cantly higher in women than that in men. These results are 
similar with those at the national level. The incidence of hyper-
tension in whole life has been rising in 10-year recently and is 
now 90% in the US [19]. A national study of the US (NHANESA) 
from 2005 to 2008 reported that 33.5% of the US adults 20 
years old or more have hypertension, and the hypertension 
prevalence is almost same status between the genders [9]. 
Moreover, the prevalence of hypertension tends to increase 
with age and reaches nearly 57% in male and 61% in female in 
those 65 to 74 years in the US [15]. Glaser et al. [20] from the 
Treat Angina with Aggrastat and Determine Cost of Therapy 
with an Invasive or Conservative Strategy-Thrombolysis in 
Myocardial Infarction 18 (TACTICS-TIMI 18) study reported that 
women patients were older and had higher rates of hyperten-
sion than the men did.
In this study, total cholesterol and LDL-C decreased continu-
ously over time, but HDL-C increased overall. These results 
were consistent with that of previous studies. In the INTER-
HEART study, dyslipidemia was the most important CVD risk 
factor [3]. Dyslipidemia is defined by increased triglyceride lev-
els (≥150 mg/dL), decreased HDL-C levels (<40 mg/dL), and 
increased LDL-C [17]. Hypertriglyceridemia also is known as an 
Figure 4. Trends of other cardiovascular risk factors including 
body mass index (A), history of hypercholesterolemia (>240 
mg/dL) (B), and history of myocardial infarction (C) by gender 
in percutaneous coronary intervention patients from 1994 to 
2010.
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Figure 5. Trend of medication use at baseline (A) and on discharge (B) by gender in percutaneous coronary intervention patients 
from 1994 to 2010. ACE, angiotensin converting enzyme.
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independent CHD risk factor. Because it was associated with 
increased status in atherogenic particles. LDL-C also are strong 
atherogenic and lead to rapid onset of CHD. The Adult Treat-
ment Panel III suggested a fasting triglyceride objective of 
<150 mg/dL [21]. Many kinds of epidemiologic studies have 
demonstrated conclusive evidence that low status of LDL-C im-
proves the patient’s prognosis of CHD [22]. The risk of CVD and 
death all-cause improved in rate to the decrease in LDL-C levels 
achieved during management [23].
Approximately 15% of the US adults 20 years of age or older 
have total cholesterol levels≥240 mg/dL [9]. In our PCI pa-
tients, the prevalence of hypercholesterolemia was average at 
78.0%. The proportion of all patients with a history of hyper-
cholesterolemia increased over time, and this trend differed 
between genders.
Systolic BP dramatically declined at two critical points in 
1997 and 2003. Diastolic BP also declined in a similar pattern 
with systolic BP, and these two critical points were the same 
points when the hypertension guidelines changed. In 1976, 
the Joint National Committee on Prevention, Detection, Evalu-
ation, and Treatment of High Blood Pressure published the re-
port firstly, and the most recent report JNC 7 was released in 
2003. The Adult Treatment Panel published clinical guidelines 
on the Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults in 1988, and succeeded by the second 
and third versions and an update in 2004. The Clinical Guide-
lines on the Identification, Evaluation, and Treatment of Over-
weight and Obesity in Adults were published in 1998. We be-
lieve that by following the updated hypertension guidelines 
toward medication use, blood pressure and lipid profiles im-
proved in our study population.
DM contributes to raised morbidity and mortality, and con-
tributes to CVD complications [24]. DM patients are at markedly 
increased risk of CHD, silent myocardial ischemia and MI [17]. 
Additionally, DM patients are prone to hypertension cause by 
increased activity in the renin-angiotensin-aldosterone system, 
salt retention, and highly stimulated sympathetic nerve system. 
Within the population, the proportion of patients who develop 
diabetes is increasing in recent decades [25]. In 2008, the Amer-
ican Heart Association estimated that there are 18 300 000 DM 
patients in the US, representing 8% of the adult population, and 
that the prevalence of DM is dramatically increasing [9]. Statis-
tics report that two epidemics of obesity and DM may see a re-
versal in the dramatic improvement made against CVD in 10-
year recently [17,22]. The dramatic elevated in obesity over the 
two decade has led to an increase in type 2 women DM [15]. 
The proportion of DM increased 7.0% (men 9.0%, women 
3.0%) per year between 1994 to 1999 and 2006 to 2010. Gan-
dhi et al. [26] reported that the proportion of MI with DM ele-
vated 3% in one year from 1979 to 1998 in Olmsted County, 
Minnesota. It is consistent with other studies that the preva-
lence of DM in female is higher than that in male, so DM is a 
strong risk factor in female [27]. However, in this study, the pro-
portion of DM patients is increasing at a faster rate in men than 
that in women; relative changes from 1994-1999 to 2006-2010 
were 9.0% in men, 3.0 % in women.
The long-term health effects of smoking on CVD are serious, 
and a dose-response relationship was known between the sta-
tus of smoking and the incidence of MI [3]. Cigarette smoking 
is harmful at any age. Furthermore, smoking acts synergistical-
ly co-act with other traditional cvRFs to dramatically increase 
the risk related with each risk factor individually [28]. In this 
study, although the prevalence of current smokers was stable 
over time, the prevalence of ever-smokers decreased in men 
patients (p<0.001), but increased in women patients (p=0.042). 
Our results were inconsistent with a report from 2005; the tem-
poral decrease in smoking showed among MI patients is con-
sistent with the general population over the past few decades 
[29]. Despite four decades of progress, 21% of male and 17.5% 
of female continued smoke cigarettes among all American ≥
18 years of age as of 2010 [9].
Excess weight is independently associated with increased 
CHD risk in both genders [30]. A high BMI was most important 
contributing factor of mortality from CVD [31]. BMI has report-
ed a graded inter-relationship with MI [17]. Obesity also ex-
plains the increasing prevalence of acute MI in younger pa-
tients [32]. Obesity in abdomen has been connected with met-
abolic disorder, such as hypertriglyceridemia, hyperinsulinemia, 
insulin resistance, hypertension, and DM. The temporal increas-
es in obesity observed for MI cases are consistent with trends 
over time in recent decades [29]. There has been a dramatic ep-
idemics in overweight and obesity over the past 25 years in the 
America [33], with the obesity rate among the adult population 
having risen from 15% in 1980 to 34% in 2008 [34]. In our pop-
ulation PCI patients, mean BMI increased over time in the total 
population and in men and women separately. Nevertheless, 
the trends and clinical meaning of these trends for PCI patients 
remain vague. 
It also is important to recognize the trend of medication 
therapy over time among our PCI patients, particularly isch-
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emic events after PCI are commonly associated with thrombo-
embolism [35]. We identified the trends of pharmacological 
drugs for treatment over time. The use of most of medications 
increased over time, however β-blocker and ACE inhibitor use 
dramatically declined after 2007 and 2006, respectively, at 
baseline and upon discharge. The results showed significant 
trend difference between men and women in the use of ACE 
inhibitor and lipid lowering drugs at discharge. Increasing 
trend of drug use was consistent with the results of other stud-
ies. In community study, the trends of temporal medication 
use increased, and earlier studies suggested a low status of us-
ing evidence-based management after MI, especially among 
older people, women, and DM patients [36]. Women have 
been found less likely than men are to receive thrombolytic 
therapy, aspirin, heparin, and β-blockers [37]. Perschbacher et 
al. [36] reported the application of ACE inhibitors, aspirin, and 
β-blockers to average 42%, 75%, and 44% using administrative 
data (1994 to 1997) and 72%, 91%, and 33% according to com-
munity surveillance studies (1993 to 1998), respectively. In this 
study, use of ACE inhibitors and β-blockers in PCI patients in-
creased over time, but abruptly declined after 2006 and 2008, 
respectively. This situation can be due to discourage applica-
tion of β-blockers and replaced ACE inhibitors by angiotensin 
receptor blockers. It have been proposed to include β-blockers 
in hypertension guidelines as a first therapeutic choice for 
over 30-year. However, controversy over the use and effective-
ness of β-blockers in CVD exist. Currently, older β-blockers are 
not typically a first choice in the treatment of primary hyper-
tension because of various controversies and introduction of 
novel drug [38]. Based on evidence from randomized clinical 
trials, the American College of Cardiology and American Heart 
Association guidelines recommend the application of ACE in-
hibitors in chronic heart failure or MI and left ventricular dys-
function patients, while angiotensin receptor blockers are re-
served for those who cannot treat ACE inhibitors [39]. Angio-
tensin receptor blockers afford well-known efficacy and indi-
cation that make sure their many medication alternatives, in-
cluding those subject to the adverse effects of ACE inhibitors 
medication [40].
This study could limit its broad application and generaliza-
tion because of a retrospective analysis from a single institu-
tion, but represents the largest temporal trends analysis of cor-
onary risk factors in patients undergoing PCI over time. We did 
not comment on trends in genetic factors, related environmen-
tal factors, other conventional risk factors, and clinical charac-
teristics and outcomes. Our study cannot rule out selection bias 
as the patients referred for tertiary-level care centers may in-
clude more severe cases of CHD than that in the general popu-
lation. Since the FRS commonly estimate risk in the healthy 
person, PCI patients will show an essentially higher risk score 
than that in the general people. Therefore, the result of this 
study should be further examined in different another settings. 
The quality of our data relies on the quality of the hospital cod-
ing of the PCI registry. There can be some miscoding and re-
porting errors of cvRFs and related data. The characteristics of 
this study were described as natural and controlling for con-
founder like sex or age was not performed. Further studies are 
needed to identify these differences.
We have demonstrated that the FRS, 10-year CVD risk, BP, 
and lipid profiles improved over time in patients who under-
went a PCI. The age distribution significantly shifted toward old-
er age with time, but the gender distribution did not changed. 
However, obesity, history of hypercholesterolemia, and comor-
bidities like hypertension and diabetes increased substantially. 
The decreased overall CVD risk likely originated from the signif-
icant improvement in the BP and lipid profiles due to medica-
tion use. Furthermore, we observed that the FRS, 10-year CVD 
risk, systolic BP, diastolic BP, LDL-C, DM, hypertension, BMI, and 
history of hypercholesterolemia had a significantly different 
trend between men and women. However, age, total choles-
terol, HDL-C, and the proportion of current smokers did not 
change with time. The use of most of the medications marked-
ly increased over time; however, β-blockers and ACE inhibitors 
dramatically declined. Moreover, a significant trend difference 
between the genders in the use of ACE inhibitor and lipid low-
ering drug on discharge was found. 
Thus, the results of our study suggest that future studies and 
clinical and public interventions are needed to evaluate these 
differences.
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Supplemental Table 1. Trends of the Framingham risk score and its component by gender and 5-year interval
Variables
Total 
population
(n=25 519)
5-Year interval Relative
change
(difference, %)
p for 
trend11994-1999
(n=8539)
2000-2005
(n=9729)
2006-2010
(n=7251)
Total population  
   Framingham risk score 7.0 (3.3) 7.4 (3.2) 7.1 (3.3) 6.5 (3.2) -0.9 <0.001
   10-Year CVD risk (%)    11.0 (7.0,18.0) 11.0 (8.0,18.0) 11.0 (7.0,18.0) 11.0 (7.0,14.0) 0 <0.001
   Age (y) 66.5 (12.1) 65.5 (11.8) 66.9 (12.1) 67.2 (12.3) 1.7 <0.001
   Male gender 18 068 (71.0) 6041 (71.0) 6861 (71.0) 5166 (71.0) 0 0.52
   SBP (mmHg) 128.8 (22.1) 136.8 (21.9) 131.2 (22.4) 121.9 (19.7) -14.9 <0.001
   DBP (mmHg) 70.2 (13.4) 75.6 (12.5) 70.6 (13.4) 67.1 (13.0) -8.5 <0.001
   Hypertension 17 785 (72.0)   5095 (61.0) 6982 (75.0) 5708 (82.0) 21 <0.001
   LDL (mg/dL) 104.3 (38.5) 119.7 (37.5) 101.6 (36.5) 94.0 (37.8) -25.7 <0.001
   TC (mg/dL) 177.4 (45.8 ) 194.1 (45.0) 174.9 (42.1) 165.8 (46.9) -28.3 <0.001
   HDL (mg/dL) 43.6 (12.8) 42.5 (12.3) 44.2 (12.6) 43.7 (13.4) 1.2 <0.001
   DM  6564 (26.0) 1891 (22.0) 2574 (27.0) 2099 (29.0) 7 <0.001
   Current smoker 4527 (18.0) 1582 (19.0) 1650 (17.0) 1295 (18.0) -1 0.22
   Ever smoker 16 088 (63.0) 5431 (64.0) 6134 (63.0) 4523 (62.0) -2 0.11
Men
   Framingham risk score 6.3 (2.6) 6.5 (2.5) 6.4 (2.7) 6.0 (2.5) -0.5 <0.001
   10-Year CVD risk (%) 11.0 (9.0,18.0) 14 (9.0,18.0) 11. (9.0,18.0) 11.0 (7.0,18.0) -3 <0.001
   Age (y) 65.3 (11.8) 64.2 (11.5) 65.6 (11.8) 66.0 (12.0) 1.8 <0.001
   SBP (mmHg) 128.2 (21.4) 135.4 (21.2) 130.6 (21.9) 121.7 (19.1) -13.7 <0.001
   DBP (mmHg) 71.3 (13.0) 76.3 (12.3) 71.4 (13.1) 68.6 (12.6) -7.7 <0.001
   Hypertension 12 078 (69.0) 3355 (57.0) 4733 (73.0) 3990 (80.0) 23 <0.001
   LDL (mg/dL) 103.2 (37.4) 118.4 (35.6) 100.7 (35.8) 92.4 (36.6) -26 <0.001
   TC (mg/dL) 174.0 (44.8) 190.3 (43.5) 171.6 (40.8) 162.1 (46.5) -28.2 <0.001
   HDL (mg/dL) 41.4 (11.4) 40.5 (10.8) 42.0 (11.2) 41.4 (12.0) 0.9 <0.001
   DM 4319 (24.0) 1163 (19.0) 1723 (25.0) 1433 (28.0) 9 <0.001
   Current smoker 3324 (18.0) 1170 (19.0) 1206 (18.0) 948 (18.0) -1 0.14
   Ever smoker 12 542 (69.0) 4286 (71.0) 4750 (69.0) 3506 (68.0) -3 <0.001
Women
   Framingham risk score 8.9 (4.0) 9.6 (3.6) 8.9 (4.0) 8.0 (4.2) -1.6 <0.001
   10-Year CVD risk (%) 9.0 (7.0,15.0) 9.0 (8.0,15.0) 9.0 (6.0,15.0) 8.0 (5.0,13.0) -1 <0.001
   Age (y) 69.5 (12.2) 68.7 (11.7) 69.9 (12.4) 70.0 (12.7) 1.3 <0.001
   SBP (mmHg) 130.3 (23.6) 140.6 (23.5) 132.6 (23.6) 122.6 (21.1) -18 <0.001
   DBP (mmHg) 67.5 (14.0) 73.7 (13.0) 68.4 (13.8) 63.3 (13.5) -10.4 <0.001
   Hypertension 5707 (79.0) 1,740 (71.0) 2249 (82.0) 1718 (85.0) 14 <0.001
   LDL (mg/dL) 107.1 (41.1) 123.3 (41.9) 103.8 (38.0) 97.9 (40.4) -25.4 <0.001
   TC (mg/dL) 186.2 (47.2) 204.7 (47.3) 182.9 (44.1) 175.0 (46.7) -29.7 <0.001
   HDL (mg/dL) 49.2 (14.4) 47.8 (14.2) 49.8 (14.1) 49.6 (14.8) 1.8 <0.001
   DM  2245 (30.0) 728 (29.0) 851 (30.0) 666 (32.0) 3 0.04
   Current smoker 1203 (16.0) 412 (16.0) 444 (15.0) 347 (17.0) 1 0.95
   Ever smoker 3546 (48.0) 1145 (46.0) 1384 (48.0) 1017 (49.0) 3 0.042
Values are presented as mean±SD, number of patients (%), or median (quartiles 1, 3).
CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; TC, total cholesterol;  HDL, high density lipo-
protein; DM, diabetic mellitus.
1A linear regression analysis was used to assess the trend for continuous variables, and the Cochran-Armitage trend test was used for the comparison of propor-
tions. 
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Supplemental Table 2. Trend of non-Framingham risk score variables for coronary heart disease by gender and 5-year interval
Variables
Total 
population
(n=25 519)
5-Year interval Relative
change
(difference, %)
p for 
trend11994-1999
(n=8539)
2000-2005
(n=9729)
2006-2010
(n=7251)
Total population  
   Body mass index (kg/m2)                    29.6 (5.7) 28.9 (5.2) 29.7 (5.7) 30.3 (6.1) 1.4 <0.001
   History of hypercholesterolemia2 18 182 (78.0) 4849 (63.0) 7489 (84.0) 5844 (85.0) 22 <0.001
   History of myocardial infarction3 8032 (32.0) 2875 (34.0) 3044 (32.0) 2113 (30.0) -4 <0.001
Men
   Body mass index (kg/m2) 29.6 (5.3) 28.8 (4.7) 29.8 (5.3) 30.4 (5.7) 1 <0.001
   History of hypercholesterolemia 12 740 (77.0) 3293 (61.0) 5255 (84.0) 4192 (85.0) 24 <0.001
   History of myocardial infarction 5925 (33.0) 2103 (35.0) 2237 (33.0) 1585 (31.0) -4 <0.001
Women  
   Body mass index (kg/m2) 29.6 (6.7) 29.2 (6.1) 29.6 (6.7) 30.2 (7.1) 1 <0.001
   History hypercholesterolemia 5442 (80.0) 1556 (70.0) 2234 (85.0) 1652 (84.0) 14 <0.001
   History of myocardial infarction 2107 (29.0) 772 (31.0) 807 (29.0) 528 (26.0) -5 <0.001
Values are presented as mean±SD or number of patients (%).
1A linear regression analysis was used to assess the trend for continuous variables, and the Cochran-Armitage trend test was used for the comparison of propor-
tions. 
2Hypercholesterolemia was defined that a total cholesterol blood level≥240 mg/dL.
3A history of myocardial infarction was defined as a myocardial infarction event within 7 days of the percutaneous coronary intervention.
229
CVD Risk Factors in PCI Patients
Supplemental Table 3. Trend of pharmaceutical therapy use by gender and 5-year interval
Variable
Total 
population
(n=25 519)
5-Year interval Relative
change
(difference, %)
p for 
trend11994-1999
(n=8539)
2000-2005
(n=9729)
2006-2010
(n=7251)
Total population  
  Aspirin use at baseline2 22 149 (87.0) 6806 (80.0) 8391 (87.0) 6952 (96.0) 16 <0.001
  Beta-blocker use at baseline 18 284 (72.0) 5373 (63.0) 7214 (75.0) 5697 (79.0) 16 <0.001
  ACE inhibitor use at baseline   9119 (36.0) 1733 (20.0) 3799 (40.0) 3587 (50.0) 30 <0.001
  Lipid lowering drug use at baseline 12 767 (51.0) 2505 (30.0) 5128 (54.0) 5134 (71.0) 29 <0.001
  Aspirin use at discharge 24 076 (96.0) 7892 (94.0) 9171 (95.0) 7013 (98.0) 4 <0.001
  Beta-blocker use at discharge 19 938 (79.0) 5761 (68.0) 7901 (82.0) 6276 (88.0) 20 <0.001
  ACE inhibitor use at discharge 12 256 (49.0) 2392 (28.0) 5437 (57.0) 4427 (62.0) 34 <0.001
  Lipid lowering drug use at discharge 18 676 (74.0) 4080 (48.0) 7978 (83.0) 6618 (92.0) 44 <0.001
Men 
  Aspirin use at baseline 15 738 (88.0) 4825 (80.0) 5936 (88.0) 4977 (97.0) 17 <0.001
  Beta-blocker use at baseline 12 841 (72.0) 3746 (62.0) 5054 (75.0) 4041 (79.0) 17 <0.001
  ACE inhibitor use at baseline 6362 (35.0) 1183 (20.0) 2634 (39.0) 2545 (49.0) 29 <0.001
  Lipid lowering drug use at baseline 9184 (52.0) 1792 (30.0) 3679 (55.0) 3713 (72.0) 42 <0.001
  Aspirin use at discharge 17 161 (96.0) 5640 (94.0) 6511 (96.0) 5010 (98.0) 4 <0.001
  Beta-blocker use at discharge 14 100 (79.0) 4054 (68.0) 5577 (82.0) 4469 (87.0) 19 <0.001
  ACE inhibitor use at discharge   8595 (48.0) 1630 (27.0) 3790 (56.0) 3175 (62.0) 33 <0.001
  Lipid lowering drug use at discharge 13 370 (75.0) 2920 (49.0) 5712 (84.0) 4738 (93.0) 54 <0.001
Women 
  Aspirin use at baseline 6411 (87.0) 1981 (80.0) 2455 (87.0) 1975 (95.0) 15 <0.001
  Beta-blocker use at baseline 5443 (74.0) 1627 (65.0) 2160 (77.0) 1656 (80.0) 15 <0.001
  ACE inhibitor use at baseline 2757 (37.0) 550 (22.0) 1165 (41.0) 1042 (50.0) 28 <0.001
  Lipid lowering drug use at baseline 3538 (49.0) 713 (29.0) 1449 (52.0) 1421 (68.0) 39 <0.001
  Aspirin use at discharge 6915 (94.0) 2252 (92.0) 2660 (94.0) 2003 (97.0) 5 <0.001
  Beta-blocker use at discharge 5838 (80.0) 1707 (70.0) 2324 (82.0) 1807 (88.0) 18 <0.001
  ACE inhibitor use at discharge 3661 (50.0) 762 (31.0) 1647 (58.0) 1252 (61.0) 30 <0.001
  Lipid lowering drug use at discharge 5306 (72.0) 1160 (47.0) 2266 (81.0) 1880 (91.0) 44 <0.001
Values are presented as number of patients (%).
ACE, angiotensin converting enzyme.
1The Cochran-Armitage trend test was used to compare the proportions. 
2Mean value at baseline for answering “yes” to whether the medication was used within 3 days before the percutaneous coronary intervention.
